You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Challenges in introducing lung cancer screening outlined by NCCP

By Dermot - 21st Jan 2020 | 6 views

There is a need for “considerable further work” to be completed before a decision on whether to introduce lung cancer screening in Ireland is made, according to the former Assistant National Director/Director of Public Health at the National Cancer Control Programme (NCCP). Dr Marie Laffoy, who has since retired, was writing to Mr Michael Conroy, Principal Officer in the Cancer Bloods and Organs Policy division of the Department of Health at the end of 2018 in relation to the Irish Cancer Society’s (ICS) position paper on lung cancer. She wrote that work that needs to be undertaken includes the timing of conducting a health technology assessment and a “cost-effectiveness assessment on lung cancer screening”.

“Challenges have been identified in all the trials, and these would need to be sorted,” according to Dr Laffoy.

Identifying the population at risk is a major challenge, she wrote. These include asymptomatic smokers aged between 55 and 70 with a 30-pack year history and ex-smokers who stopped smoking for a number of years.

“Defining the population denominator is difficult but critical,” stated Dr Laffoy. She also underlined the need for investment in infrastructures, equipment, and staff.

Dr Laffoy later forwarded summaries she wrote of two presentations delivered at the 2019 British Thoracic Oncology Group (BTOG) meeting delivered by Prof Harry de Koning, author of the NELSON Trial, and Prof Bob Steele, Chair of the UK National Screening Committee. The NELSON study found that lung cancer screening showed a 26 per cent mortality reduction in men and considerable reduction in false positives compared to previous trials.

“That said, both of the presenters acknowledged that there is a lot of work to be done at European level to bring the impact of the trial into a population-based screening programme,” according to Dr Laffoy.

The Minister for Health Simon Harris established the National Screening Advisory Committee in 2019 to advise on all new proposals for population-based screening programmes and revisions to existing programmes.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]